摘要
目的探讨C-12多肿瘤标志物蛋白质芯片检测系统在肺癌诊断中的临床应用价值。方法采用C-12多肿瘤标志物蛋白质芯片检测系统检测172例肺癌患者以及肺良性病变患者52例。所有肺癌均经细胞学或组织学确诊,其中肺鳞癌89例,肺腺癌72例,肺小细胞癌11例;Ⅰ期12例,Ⅱ期28例,Ⅲ期65例,Ⅳ期67例。血清中检测的12种常见肿瘤标志物为:CA199、NSE、CEA、CA242、CA125、CA153、AFP、Ferrtin、free-PSA、PSA、HGH、β-HCG。结果172例肺癌患者有128例血清肿瘤标志物为阳性,阳性率为74.42%;52例肺良性病变患者有5例血清肿瘤标志物阳性,阳性率为9·62%,两者之间有显著差异(P<0·01)。不同病理类型的肺癌患者,阳性率无显著性差异(P>0·05)。不同临床分期的肺癌患者阳性率存在显著性差异,以Ⅳ期总阳性率最高,为79·2%(P<0·05)。单项肿瘤标志物检测与C-12芯片的联合检测肺癌的阳性率有明显的差异(P<0·01)。结论C-12多肿瘤标志物蛋白质芯片的应用对肺癌的诊断有较高的临床参考价值。
Objective To evaluate the diagnosis value of C-12 multiple tumor marker protein chip detective system for lung cancer. Methods The serum levels of 12 tumor makers were measured in 172 lung cancer patiens,52 pulmonary benign diseases patients. All lung cancer patients were definitly diagnosised by cytology or histology, including 89 squamous cell carcinoma patients, 72 bronchogenic adenocarcinoma patients, 11 small cell lung cancer patients; 12 patients in stage Ⅰ, 28 patients in stageⅡ, 65 patients in stage Ⅲ, 67 patients in stage IV. The 12 common tumor markers in serum included CA199, NSE, CEA, CA242, CA125, CA153, AFP, Ferrtin, free-PSA, PSA, HGH, 13-HCG. Resulls At least one kind of tumor maker was found higher in 128 of the 172 lung cancer patients, the positive rate was 74. 42%, and in 5 of the 52 pulmonary benign diseases patients, the positive rate was 9. 62% ,it is statistical significance between two the groups (P〈0. 01 ). The positive rate was not statistical significance (P〈0. 05) in different pathological types lung cancer patients . The positive rate was statistical significance in different stage lung cancer patients , the highest positive rate which in stage IV patients was 79. 2~ (P^0. 05). It is statistical significance between the positive rate of one tumor marker detective system and C-12 multiple tumor marker protein chip detective system for lung cancer(P〈0. 01 ). Conclusion The application of C-12 multiple tumor protein chip measurement in diamaosis of lung cancer was helpful in clinic.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2006年第4期349-350,共2页
Medical Journal of Chinese People's Liberation Army